Leman Biotech Co., Ltd. announced encouraging clinical progress for META 10-19, its proprietary metabolically armored CD19-targeted CAR-T therapy. The first patient with mantle cell lymphoma (MCL) treated without lymphodepleting preconditioning achieved complete remission (CR).
This outcome provides clinical validation of the company’s pioneering “ultra-low-dose + lymphodepletion-free” strategy across both hematologic malignancies and autoimmune diseases. The approach challenges the long-standing paradigm that effective CAR-T therapy requires high cell doses combined with lymphodepleting chemotherapy.
By eliminating pre-conditioning and using substantially lower cell doses, this strategy has the potential not only to reduce treatment-related toxicity, shorten recovery time, and preserve endogenous immunity, but also to significantly lower overall costs by eliminating the need for chemotherapy, reducing hospitalization requirements, and minimizing the burden of managing preconditioning-related complications. Importantly, it may expand access to frail or heavily pretreated patients who are often ineligible for preconditioning regimens.
